South Africa: Testing Stool Can Help Detect TB in Children
[spotlight] Most tuberculosis (TB) testing today relies on sputum samples coughed up from the lungs. This makes intuitive sense since pulmonary (or lung) TB is the most common form of TB and sputum provides testable samples straight from the scene of infection. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - December 7, 2022 Category: Infectious Diseases Source Type: news

How Gene Editing Could Help Solve the Problem of Poor Cholesterol
Cardiovascular disease is the leading cause of death in the U.S. and around the world. Though it’s held the top spot for decades, it wasn’t always the king of mortal maladies. Its ascension was propelled by two of medical science’s greatest successes. “Before the 20th century, heart disease was an uncommon cause of death,” says Dr. Michael Shapiro, a professor of cardiology at the Wake Forest University School of Medicine. Bacterial infections such as tuberculosis and dysentery, as well as smallpox and other contagious viruses, were common killers. “Antibiotics and vaccines changed every...
Source: TIME: Health - December 6, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news

Infant BCG Vaccine Protects Only Those Under Age 5 Years Infant BCG Vaccine Protects Only Those Under Age 5 Years
Although the BCG vaccine may keep severe forms of tuberculosis, meningitis, and miliary tuberculosis at bay, its efficacy and effectiveness against pulmonary tuberculosis are low.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 5, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news

South Africa: South Africa's Prisons Are a Breeding Ground for the Spread of TB. Our Model Shows How
[The Conversation Africa] South African prisons are famously overcrowded. Prison populations are believed to exceed capacity by an overall 33%, although that number jumps to over 200% at some facilities, according to recent reports. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - December 1, 2022 Category: Infectious Diseases Source Type: news

South Africa: New Resistance Tests Set to Improve TB Treatment
[spotlight] Some strains of the tuberculosis (TB) bacterium have mutated to become resistant to some of the drugs commonly used to treat TB. Accordingly, one of the first questions to ask when someone has TB is which drugs will be effective in fighting that person's TB. Unfortunately, quick answers to this question are not always available. As a consequence, people are at times treated with drugs that won't work for their particular strain of TB. What's worse, these drugs often have significant side effects. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 28, 2022 Category: African Health Source Type: news

USPSTF Recommends Screening for Latent TB Infection
TUESDAY, Nov. 22, 2022 -- The U.S. Preventive Services Task Force (USPSTF) recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk. This recommendation forms the basis of a draft recommendation statement,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 22, 2022 Category: Pharmaceuticals Source Type: news

South Africa: Mental Health Screening for People With TB Will Change Lives and Boost SA's TB Response
[spotlight] After two years of COVID-19 and disruption of normal healthcare services such as those for tuberculosis (TB), welcome-back initiatives were started across provinces to get people back on treatment and back into care. Spotlight reported on some of these campaigns here. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - November 22, 2022 Category: Infectious Diseases Source Type: news

Study Affirms Shorter Regimens for Drug-Resistant Tuberculosis Study Affirms Shorter Regimens for Drug-Resistant Tuberculosis
Two short-course bedaquiline-containing regimens are promising treatment options for multidrug-resistant tuberculosis.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 17, 2022 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis. (Source: World Pharma News)
Source: World Pharma News - November 17, 2022 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

UK Pledges $1.19 Billion to Fight Diseases in Poor Countries
The contribution to the Global Fund is less than aid organizations had hoped for. Britain has been cutting foreign aid since 2020. (Source: NYT Health)
Source: NYT Health - November 15, 2022 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Acquired Immune Deficiency Syndrome Malaria Foreign Aid Tuberculosis Philanthropy Humanitarian Aid Great Britain Source Type: news

Less and Late: UK Gives $1 Billion to Global Disease Fight Less and Late: UK Gives $1 Billion to Global Disease Fight
The British government said on Monday it would contribute 1 billion pounds ($1.18 billion) to the Global Fund to fight AIDS, tuberculosis, and malaria, more than 6 weeks after other countries made their commitments.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 15, 2022 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Johnson & Johnson Rises to #2 in Ranking of Companies ’ Efforts to Expand Access to Medicines Worldwide
Everyone should have the opportunity to lead a healthy life. This requires that we advance equitable access to healthcare and address some of the world’s most devastating and neglected diseases.We are proud that Johnson & Johnson’s actions to expand access to our medicines and focus on addressing diseases that disproportionately impact people in lower- and middle-income countries has made us the 2nd-ranked company globally in the 2022 Access to Medicine Index.Our industry-leading performance marks an improvement, up from 3rd in 2021, and is the sixth consecutive time we are featured as a top three performer by the ...
Source: Johnson and Johnson - November 15, 2022 Category: Pharmaceuticals Source Type: news

Africa: TB Treatment Can Be Cut to Two Months for Some, Finds Landmark Study
[spotlight] Some cases of tuberculosis (TB) can be successfully treated in as little as two months - a third of the current standard of six months in South Africa and most other countries. This is according to early findings from the landmark TRUNCATE TB trial presented at last week's Union World Conference on Lung Health. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 15, 2022 Category: African Health Source Type: news

Why Masks Still Matter
During the COVID-19 pandemic, masks were weaponized for partisan purposes. “The politicization of mask use,” says William Hanage, infectious disease epidemiologist at Harvard University, “makes as much sense as politicizing gravity.” Masks are simply a tool—a protective barrier—that can help to reduce the spread of respiratory infections, just as condoms are a barrier that can reduce the spread of sexually transmitted infections. And as we head into winter, with rising rates of multiple respiratory viruses, including flu, RSV, and new coronavirus variants, masks could help all Americans ...
Source: TIME: Health - November 14, 2022 Category: Consumer Health News Authors: Abraar Karan and Gavin Yamey Tags: Uncategorized COVID-19 freelance Source Type: news

New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news